The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: An independent risk factor for serious pregnancy complications

Metabolism: Clinical and Experimental

Volumn 49, Issue 7, 2000, Pages 845-852

  Glueck, C J ^a,b   Phillips, Harvey ^a   Cameron, Dan ^a   Wang, Ping ^a   Fontaine, Robert N ^a   Moore, Sarah K ^a   Sieve Smith, Luann ^a   Tracy, Trent ^a  

^a JEWISH HOSPITAL   (United States)

^b Cholesterol Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GENE MUTATION; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; PLACENTA INSUFFICIENCY; POLYMERASE CHAIN REACTION; PREGNANCY COMPLICATION; PREMATURITY; PRIORITY JOURNAL; RISK FACTOR; SPONTANEOUS ABORTION; THROMBOPHILIA;

EID: 0034234399     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2000.6749     Document Type: Article

References (72)

1. 1. Younis JS, Ohel G, Brenner B, et al: Familial thrombophilia - the scientific rationale for thrombophylaxis in recurrent pregnancy loss? Hum Reprod 12:1389-1390, 1997
2. 2. Gris JC, Ripart-Neveu S, Maugard C, et al: Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 77:1096-1103, 1997
3. 3. Rai RS, Regan L, Chitolie A, et al: Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Br J Obstet Gynaecol 103:842-844, 1996
4. 4. Younis JS: Factor V Leiden - A novel etiology of the long-standing thrombosis theory for recurrent pregnancy loss. Am J Obstet Gynecol 178:1107-1108, 1998
5. 5. Ridker PM, Miletich JP, Buring JE, et al: Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 128:1000-1003, 1998
6. 6. Richards EM, Makris M, Preston FE: The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss. Br J Haematol 98:660-661, 1997
7. 7. Brenner B, Maudel H, Lanir N, et al: Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 97:551-554, 1997
8. 8. Dizon-Townson DS, Meline L, Nelson LM, et al: Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 177:402-405, 1997
9. 9. Kupferminc MJ, Eldor A, Steinman N, et al: Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 240:9-13, 1999
10. 10. Grandone E, Margaglione M, Colaizzo D, et al: Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G 20210A, and methylenetetrahydrofolate reductase 677T. Am J Obstet Gynecol 179:1324-1328, 1998
11. 11. Rand JH, Wu XX, Andree HA, et al: Pregnancy loss in the antiphospholipid-antibody syndrome - A possible thrombogenic mechanism. N Engl J Med 337:154-160, 1997
12. 12. Blomback M, Bremme K, Hellgren M, et al: Thromboprophylaxis with low molecular mass heparin 'Fragmin' (dalteparin) during pregnancy - A longitudinal safety study. Blood Coagul Fibrinolysis 9:1-9, 1998
13. 13. Riyazi N, Leeda M, de Vries JJ, et al: Low molecular weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth retardation: A preliminary study. Eur J Obstet Gynecol Reprod Biol 80:49-54, 1998
14. 14. Lima F, Khamashta MA, Buchanan NM, et al: A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 14:131-136, 1996
15. 15. Birdsall MA, Lockwood GM, Ledger WL, et al: Antiphospholipid antibodies in women having in-vitro fertilization. Hum Reprod 11:1185-1189, 1996
16. 16. Glueck CJ, Wang P, Fontaine RN, et al: Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 48:1589-1595,1999
17. 17. Gris JC, Neveu S, Mares P, et al: Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med 122:606-615, 1993
18. 18. Estelles A, Grancha S, Gilabert J, et al: Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. Am J Pathol 149:1229-1239, 1996
19. 19. Halligan A, Bonnar J, Sheppard B, et al: Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and preeclampsia. Br J Obstet Gynaecol 101:488-492, 1994
20. 20. Estelles A, Gilabert J, Grancha S, et al: Abnormal expression of type I plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost 79:500-508, 1998
21. 21. Bellart J, Gilabert R, Fontcuberta J, et al: Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation. Am J Perinatol 15:81-85, 1998
22. 22. de Vries JI, Dekker GA, Huijgens PC, et al: Hyperhomocysteinemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 104:1248-1254, 1997
23. 23. Schjetlein R, Haugen G, Wisloff F: Markers of intravascular coagulation and fibrinolysis in preeclampsia: Association with intrauterine growth retardation. Acta Obstet Gynecol Scand 76:541-546, 1997
24. 24. Glueck CJ, Wang P, Fontaine R, et al: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 48:511-519, 1999
25. 25. Glueck CJ, Tracy T, Weber K, et al: Metformin reduces weight, centripetal obesity, and LDL cholesterol in non-diabetic, morbidly obese subjects with BMI > 30. J Invest Med (in press)
26. 26. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215-1217, 1988
27. 27. Balasa VV, Gruppo RA, Glueck CJ, et al: The relationships of mutations in the methylenetetrahydrofolate reductase, prothrombin, and plasminogen activator inhibitor-1 gene to plasma levels of homocysteine, prothrombin, and plasminogen activator inhibitor-1 in children and adults. Thromb Haemost 81:739-744, 1999
28. 28. Brandt G, Gruppo R, Glueck CJ, et al: Sensitivity, specificity, and predictive value of modified assays for activated protein C resistance in children. Thromb Haemost 79:567-570, 1998
29. 29. Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113, 1995
30. 30. Glueck CJ, Bell H, Vadlamani L, et al: Heritable thrombophilia and hypofibrinolysis. Arch Ophthalmol 117:43-49, 1999
31. 31. Poort SR, Rosendaal FR, Reitsma PH, et al: A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-3703, 1996
32. 32. Cunningham FG, MacDonald PC, Gant NF, et al (eds): Williams Obstetrics (ed 20). Stamford, CT, Appleton & Lange, 1997, pp 797-853
33. 33. Hewson D, Bennett A: Childbirth research data: Medical records or women's reports. Am J Epidemiol 125:484-491, 1987
34. 34. Githens PB, Glass CA, Sloan FA, et al: Maternal recall and medical records: An examination of events during pregnancy, childbirth, and early infancy. Birth 20:136-141, 1993
35. 35. Oakley A, Rajan L, Robertson P: A comparison of different sources of information about pregnancy and childbirth. J Biosoc Sci 22:477-487, 1990
36. 36. Ridley JC, Bacrach CA, Dawson DA: Recall and reliability of interview data from older women. J Gerontol 34:94-105, 1979
37. 37. Martin CJ: Monitoring maternity services by postal questionnaire: Congruity between mothers' reports and their obstetric records. Stat Med 6:613-627, 1987
38. 38. Stewart MK, Festin M: Validation study of women's reporting and recall of major obstetric complications treated at the Philippine General Hospital. Int J Gynaecol Obstet 48:S53-S66, 1995 (suppl)
39. 39. Tilley BC, Barnes AB, Bergstralh E, et al: A comparison of pregnancy history recall and medical records. Implications for retrospective studies. Am J Epidemiol 121:269-281, 1985
40. 40. Ness RB, Grisso JA, Hirschinger N, et al: Cocaine and tobacco use and risk of spontaneous abortion. N Engl J Med 340:333-339, 1999
41. 41. Parazzini F, Chatenoud L, Tozzi L, et al: Determinants of risk of spontaneous abortions in the first trimester of pregnancy. Epidemiology 8:681-683, 1997
42. 42. Ezra Y, Schenker JG: Abortion rate in assisted reproduction - True increase? Early Pregnancy 1:171-175, 1995
43. 43. Snedecor GW, Cochran WG: Statistical Methods (ed 7). Ames, IA, Iowa State University Press, 1980
44. 44. Lang IM, Moster KM, Schleef RR: Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism. Arterioscler Thromb Vasc Biol 18:808-815, 1998
45. 45. Loskutoff DJ, Swadey M, Keeton M, et al: Regulation of PAI-1 gene expression in vivo. Thromb Haemost 70:135-137, 1993
46. 46. Van Meijer M, Pannekoek H: Structure of plasminogen activator inhibitor-1 (PAI-1) and its function in fibrinolysis: An update. Fibrinolysis 9:263-276, 1995
47. 47. Glueck CJ, Freiberg R, Gruppo R, et al: Thrombophilia and hypofibrinolysis: Reversible pathogenetic etiologies of osteonecrosis in adults and in children (Legg-Perthes Disease). AOA International Symposium on Osteonecrosis, in Urbaniak JR, Jones JP Jr (eds): Osteonecrosis: Etiology, Diagnosis, and Treatment. Rosemont, IL, American Academy of Orthopedic Surgeons, 1997, pp 105-110
48. 48. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group: ECAT angina pectoris study: Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 14:8-17, 1993
49. 49. Eriksson P, Kallin B, van't Hooft FM, et al: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855, 1995
50. 50. Ossei-Gerning N, Mansfield MW, Stickland MH, et al: Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 17:33-37, 1997
51. 51. Glueck CJ, Fontaine RN, Gupta A, et al: Myocardial infarction in a 35 year old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C. Metabolism 46:1470-1472, 1997
52. 52. Glueck CJ, Brandt G, Gruppo R, et al: Resistance to activated protein C and Legg-Perthes disease. Clin Orthop 338:139-152, 1997
53. 53. Glueck CJ, Crawford A, Roy D, et al: Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg-Perthes disease. J Bone Joint Surg 78A:3-13, 1996
54. 54. Glueck CJ, Freiberg R, Crawford A, et al: Secondhand smoke, hypofibrinolysis, and childhood osteonecrosis of the hip, Legg-Perthes disease. Clin Orthop 352:159-167, 1998
55. 55. Glueck CJ, Fontaine RN, Gruppo R, et al: The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop 366:133-146, 1999
56. 56. Glueck CJ, Freiberg R, Tracy T, et al: Thrombophilia and hypofibrinolysis: Pathoetiologies of osteonecrosis. Clin Orthop 334:43-56, 1997
57. 57. Glueck CJ, McMahon RE, Bouquot J, et al: Thrombophilia, hypofibrinolysis, and alveolar osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81:557-566, 1996
58. 58. Glueck CJ, McMahon RE, Bouquot J, et al: Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J Lab Clin Med 130:540-543, 1997
59. 59. Glueck CJ, McMahon RE, Bouquot JE, et al: A preliminary pilot study of treatment of thrombophilia and hypofibrinolysis and amelioration of the pain of osteonecrosis of the jaws. Oral Med Oral Surg Oral Pathol Oral Radiol Endod 85:64-73, 1998
60. 60. Gruppo R, Glueck CJ, McMahon RE, et al: The pathophysiology of alveolar osteonecrosis of the jaw: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. Pathophysiology of osteonecrosis of the jaw. J Lab Clin Med 127:481-489, 1996
61. 61. Van Veldhuizen PJ, Neff J, Murphey MD, et al: Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol 44:243-248, 1993
62. 62. Grancha S, Estelles A, Tormo G, et al: Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 81:516-521, 1999
63. 63. Iwai N, Shimoike H, Nakamura Y, et al: 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 136:109-114, 1998
64. 64. Ridker P, Hennekens CH, Lindpainter K, et al: Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 95:59-62, 1997
65. 65. Ardissino D, Mannucci PM, Merlani PA, et al: Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 94:46-51, 1999
66. 66. Doggen CJ, Bertina RM, Cats VM, et al: The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 82:115-120, 1999
67. 67. Sartori MT, Wiman B, Vettore S, et al: 4G/5G polymorphism of the PAI-1 gene promoter and fibrinolytic capacity in patients with deep venous thrombosis. Thromb Haemost 80:956-960, 1998
68. 68. Stegnar M, Uhrin P, Peternel P, et al: The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79:975-979, 1998
69. 69. Karrison TG, Ober C: Recurrent Miscarriage (REMIS) Study: How should data from women who do not become pregnant be handled? Control Clin Trials 19:430-439, 1998
70. 70. Ansari AH, Kirkpatrick B: Recurrent pregnancy loss. An update. J Reprod Med 43:806-814, 1998
71. 71. Redline RW, Zaragoza M, Hassold T: Prevalence of developmental and inflammatory lesions in nonmolar first-trimester spontaneous abortions. Hum Pathol 30:93-100, 1999
72. 72. Velazquez EM, Mendoza SG, Wang P, et al: Metformin therapy is associated with decreased plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism 46:454-457, 1997